Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Department of Clinical Medicine Research Institution, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Can J Gastroenterol Hepatol. 2022 May 9;2022:7982118. doi: 10.1155/2022/7982118. eCollection 2022.
To evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with immune checkpoint inhibition (camrelizumab) plus an antiangiogenic agent (apatinib) for advanced hepatocellular carcinoma (HCC).
Between March 2019 and April 2021, the clinical data of 38 patients diagnosed with advanced HCC who initially received TACE combined with camrelizumab plus apatinib were reviewed retrospectively. The objective response rate (ORR) and disease control rate (DCR) according to modified response evaluation criteria in solid tumors, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated.
At 2-3 months after initial therapy, the ORR and DCR was 50.0% (19/38) and 76.3% (29/38), respectively. The median PFS and OS were 7.3 months (range: 1.0-22.6 months) and 13.5 months (range: 2.3-24.3 months), respectively. Treatment-related AEs (grades 3-4) were observed in 25 patients (67.8%). No treatment-related deaths occurred.
The combination of TACE with camrelizumab plus apatinib for the treatment of patients with advanced HCC showed promising efficacy and a manageable safety profile.
评估经动脉化疗栓塞（TACE）联合免疫检查点抑制剂（camrelizumab）加抗血管生成药物（apatinib）治疗晚期肝细胞癌（HCC）的疗效和安全性。
回顾性分析 2019 年 3 月至 2021 年 4 月间 38 例初治接受 TACE 联合 camrelizumab 加 apatinib 治疗的晚期 HCC 患者的临床资料。根据实体瘤反应评价标准（RECIST）1.1 评价客观缓解率（ORR）和疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和不良反应（AE）。
初始治疗后 2-3 个月，ORR 和 DCR 分别为 50.0%（19/38）和 76.3%（29/38）。中位 PFS 和 OS 分别为 7.3 个月（1.0-22.6 个月）和 13.5 个月（2.3-24.3 个月）。25 例（67.8%）患者出现治疗相关不良事件（3-4 级）。无治疗相关死亡发生。
TACE 联合 camrelizumab 加 apatinib 治疗晚期 HCC 患者具有较好的疗效和可管理的安全性。
